<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1108</ReferenceId>
        <DateLastUpdated>2020-09-30-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15994800</PubmedId>
            <Abstract>The need to replace rabies immune globulin (RIG) as an essential component of rabies postexposure prophylaxis is widely acknowledged. We set out to discover a unique combination of human monoclonal antibodies (MAbs) able to replace RIG. Stringent criteria concerning neutralizing potency, affinity, breadth of neutralization, and coverage of natural rabies virus (RV) isolates and in vitro escape mutants were set for each individual antibody, and the complementarities of the two MAbs were defined at the onset. First, we identified and characterized one human MAb (CR57) with high in vitro and in vivo neutralizing potency and a broad neutralization spectrum. The linear antibody binding site was mapped on the RV glycoprotein as antigenic site I by characterizing CR57 escape mutants. Secondly, we selected using phage display a complementing antibody (CR4098) that recognized a distinct, nonoverlapping epitope (antigenic site III), showed similar neutralizing potency and breadth as CR57, and neutralized CR57 escape mutants. Reciprocally, CR57 neutralized RV variants escaping CR4098. Analysis of glycoprotein sequences of natural RV isolates revealed that the majority of strains contain both intact epitopes, and the few remaining strains contain at least one of the two. In vitro exposure of RV to the combination of CR57 and CR4098 yielded no escape mutants. In conclusion, a novel combination of human MAbs was discovered suitable to replace RIG.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>9062-8</ArticlePages>
            <ArticleTitle>Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Bakker</LastName>
                    <ForeName>Alexander B H</ForeName>
                </Author>
                <Author>
                    <LastName>Marissen</LastName>
                    <ForeName>Wilfred E</ForeName>
                </Author>
                <Author>
                    <LastName>Kramer</LastName>
                    <ForeName>R Arjen</ForeName>
                </Author>
                <Author>
                    <LastName>Rice</LastName>
                    <ForeName>Amy B</ForeName>
                </Author>
                <Author>
                    <LastName>Weldon</LastName>
                    <ForeName>William C</ForeName>
                </Author>
                <Author>
                    <LastName>Niezgoda</LastName>
                    <ForeName>Michael</ForeName>
                </Author>
                <Author>
                    <LastName>Hanlon</LastName>
                    <ForeName>Cathleen A</ForeName>
                </Author>
                <Author>
                    <LastName>Thijsse</LastName>
                    <ForeName>Sandra</ForeName>
                </Author>
                <Author>
                    <LastName>Backus</LastName>
                    <ForeName>Harold H J</ForeName>
                </Author>
                <Author>
                    <LastName>de Kruif</LastName>
                    <ForeName>John</ForeName>
                </Author>
                <Author>
                    <LastName>Dietzschold</LastName>
                    <ForeName>Bernhard</ForeName>
                </Author>
                <Author>
                    <LastName>Rupprecht</LastName>
                    <ForeName>Charles E</ForeName>
                </Author>
                <Author>
                    <LastName>Goudsmit</LastName>
                    <ForeName>Jaap</ForeName>
                </Author>
            </Authors>
            <Affiliations>Crucell Holland B.V., Archimedesweg 4, P.O. Box 2048, 2301 CA Leiden, The Netherlands.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Viral;Antigens, Viral;Glycoproteins;Immunoglobulin G;Viral Envelope Proteins;glycoprotein G, Rabies virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(immunology); Antibodies, Viral(immunology); Antigens, Viral(immunology); Cricetinae; Genotype; Glycoproteins(immunology); Immunoglobulin G(immunology); Mesocricetus; Mice; Mutation; Neutralization Tests; Rabies(prevention &amp; control); Rabies virus(genetics; immunology); Viral Envelope Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>79</Volume>
                <Issue>14</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Rabies virus 226-231</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KLCGVL</LinearSequence>
                        <StartingPosition>245</StartingPosition>
                        <EndingPosition>250</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAA47204.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11292</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Text page 9066</LocationOfData>
                <EpitopeId>31772</EpitopeId>
                <ReferenceStartingPosition>226</ReferenceStartingPosition>
                <ReferenceEndingPosition>231</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <BCellId>1865268</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>3 doses.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was generated by fusing SHM-D33 cells with human B cells from donors vaccined with Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine (virus strain Pitman Moore 1503-3M, Behringwerke, Mar-burg, FRG). The details of the immunization procedure were described in the cited references: Dietzschold B. et al. 1990. J Virol.64: 3087-3090.  [PMID: 2335829] and Champion JM, et al. 2000. J Immunol Methods. 235: 81-90. [PMID: 10675760]. The parent mAb57 (IgG2) was cloned into an IgG1 expression vector.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized rabies virus isolates from raccoon, gray fox, arctic fox, coyote, dog, skunk, bat, mongoose and strain CVS-11.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Culture Supernatant</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR57</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Street rabies virus</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>31613</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>15349</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>3 doses.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was generated by fusing SHM-D33 cells with human B cells from donors vaccined with Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine (virus strain Pitman Moore 1503-3M, Behringwerke, Mar-burg, FRG). The details of the immunization procedure were described in the cited references: Dietzschold B. et al. 1990. J Virol.64: 3087-3090.  [PMID: 2335829] and Champion JM, et al. 2000. J Immunol Methods. 235: 81-90. [PMID: 10675760]. The parent mAb57 (IgG2) was cloned into an IgG1 expression vector.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10036</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Culture Supernatant</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Monoclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>CR57</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG1</TransferredAntibodyHeavyChainType>
                                <TransferredAntibodyLightChainType>Lambda</TransferredAntibodyLightChainType>
                            </TransferredAntibodyMolecule>
                            <InVivoProcessInRecipient>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>5 doses, administered on days 0, 3, 7, 14, and 28.</DoseSchedule>
                            </InVivoProcessInRecipient>
                            <AdoptiveTransferComments>Recipient hamsters were adoptively transferred with the epitope specific mAb.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Adoptive transfer the epitope specific mAb protected Syrian hamster vaccinated with rabies vaccine from infection with the lethal rabies virus (COSRV), and no clear dose-response effect was observed.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>COSRV (coyote street RV)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>31613</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 1, 3, 4, 5 and figure 1</LocationOfData>
                        <BCellId>15348</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>3 doses.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was generated by fusing SHM-D33 cells with human B cells from donors vaccined with Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine (virus strain Pitman Moore 1503-3M, Behringwerke, Mar-burg, FRG). The details of the immunization procedure were described in the cited references: Dietzschold B. et al. 1990. J Virol.64: 3087-3090.  [PMID: 2335829] and Champion JM, et al. 2000. J Immunol Methods. 235: 81-90. [PMID: 10675760]. The parent mAb57 (IgG2) was cloned into an IgG1 expression vector.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized rabies virus CVS-11 with 1689 IU/mg neutralizing potency, which was determined in a standard RFFIT (rapid fluorescent focus inhibition test) neutralization assays. There was no correlation between affinity and neutralizing potency of this mAb to rabies virus strains ERA and CVS-11, respectively. This mAb also neutralized E98 escape viruses, which were generated from original wild-type CVS-11.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Culture Supernatant</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR57</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Rabies virus (strain CVS-11)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11294</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1, 3 and table 5</LocationOfData>
                        <BCellId>15347</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>3 doses.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was generated by fusing SHM-D33 cells with human B cells from donors vaccined with Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine (virus strain Pitman Moore 1503-3M, Behringwerke, Mar-burg, FRG). The details of the immunization procedure were described in the cited references: Dietzschold B. et al. 1990. J Virol.64: 3087-3090.  [PMID: 2335829] and Champion JM, et al. 2000. J Immunol Methods. 235: 81-90. [PMID: 10675760]. The parent mAb57 (IgG2) was cloned into an IgG1 expression vector.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>45</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.4</QuantitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Culture Supernatant</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR57</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>ABN11294.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11295</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Rabies virus discontinuous epitope</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>N355</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AAA47204.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11292</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 4</LocationOfData>
                <EpitopeId>153930</EpitopeId>
                <ReferenceRegion>N336</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope was deduced.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 1, 2, 3, 4, 5 and figure 1</LocationOfData>
                        <BCellId>1865150</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope specific mAb was selected from a phage antibody library, which was constructed by a series of IgG from RV-immunized individual.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was deduced by loss of neutralization of wild type CVS-11 escape virues (E98-2, 4, 5, 6, 7) with the epitope specific mAb. The mAb neutralized wild type CVS-11 and escape virues (E57A2, A3, B1, B2, B3, and C3), which was determined in a standard RFFIT (rapid fluorescent focus inhibition test) neutralization assays. There was no correlation between affinity and neutralizing potency of this mAb to rabies virus strain ERA and CVS-11, respectively.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Displayed Ab(s)</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Display Library</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR4098</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Rabies virus (strain CVS-11)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11294</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1865151</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope specific mAb was selected from a phage antibody library, which was constructed by a series of IgG from RV-immunized individual.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10036</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Displayed Ab(s)</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Display Library</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>CR4098</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG1</TransferredAntibodyHeavyChainType>
                                <TransferredAntibodyLightChainType>Kappa</TransferredAntibodyLightChainType>
                            </TransferredAntibodyMolecule>
                            <InVivoProcessInRecipient>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>5 doses, administered on days 0, 3, 7, 14, and 28.</DoseSchedule>
                            </InVivoProcessInRecipient>
                            <AdoptiveTransferComments>Recipient hamsters were adoptively transferred with the epitope specific mAb.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Adoptive transfer the epitope specific mAb protected Syrian hamster vaccinated with rabies vaccine from infection with the lethal rabies virus (COSRV), and no clear dose-response effect was observed.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>COSRV (coyote street RV)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>31613</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1, 3 and table 5</LocationOfData>
                        <BCellId>15350</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope specific mAb was selected from a phage antibody library, which was constructed by a series of IgG from RV-immunized individual.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>45</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>4.5</QuantitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Displayed Ab(s)</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Display Library</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR4098</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>ABN11294.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11295</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <BCellId>1865359</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope specific mAb was selected from a phage antibody library, which was constructed by a series of IgG from RV-immunized individual.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized rabies virus isolates from raccoon, gray fox, arctic fox, coyote, dog, skunk, bat, mongoose and strain CVS-11.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Displayed Ab(s)</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Display Library</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR4098</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Street rabies virus</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>31613</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

